AbbVie Inc.

  • Understanding The Massive Market Potential of Monoclonal Antibodies

    By Leo Sun - August 19, 2013 | Tickers: ABBV, LLY, JNJ, RHHBY

    Over the past several years, monoclonal antibodies have revolutionized cancer treatments. Monoclonal antibodies are laboratory-produced molecules which mimic naturally produced antibodies, forming the foundation of cutting edge oncology treatments, such as antibody drug conjugates (ADCs), biologics, and immunotherapy, which all aim to reduce or eliminate the use of traditional chemotherapy.

    Monoclonal antibodies, which are administered intravenously, have a wide variety of applications, including cancer cell marking, growth signal blocking, the more »

  • 2 Drug Companies to Buy and 1 to Sell

    By Phillip Woolgar - August 15, 2013 | Tickers: ABBV, GILD, SNY

    Drug companies need to consistently develop their product lines in order to fend off competition, much of which is generated from generic drugs. These firms are constantly setting their sights on the next development, so they can develop a patent and help ensure they create an economic moat. That isn't easy, however, as patents expire and these firms need to innovate once again.

    Two of these three firms are more »

  • Gilead Races against Competitors for an Oral Hepatitis C Cure

    By Todd Campbell - August 13, 2013 | Tickers: ABBV, GILD, MRK, VRTX

    The search for a hepatitis C cure is one of the most active areas within biotechnology research and development.

    One of the company's ushering in the next generation of hepatitis C treatment is Gilead Pharmaceuticals (NASDAQ: GILD). The company acquired hepatitis C drug sofosbuvir in its $11.2 billion acquisition of Pharmasset back in January 2012.

    Sonosbuvir has a very good chance of beating rival drugs to the market more »

  • Healthcare Stocks to Consider Buying

    By David Gould - July 26, 2013 | Tickers: ABT, ABBV, LLY, STJ

    Note: This article has been amended to remove TRADJENTA as Eli Lilly's leading products--it is developed and commercialized through an alliance between Eli Lilly and Boehringer Ingelheim International GmbH & Co

    To address the patent cliff, several large pharmaceutical companies have been actively reinventing their businesses in terms of pipeline updates and strategic changes. Below, I present my take on two leading producers with a focus on the headwinds and more »

  • Expanding Labels to Expand Margins

    By Seth Robey - July 18, 2013 | Tickers: ABBV, AMGN, CELG, JNJ, ONXX, PFE

    In an industry where buyouts are commonplace and small-cap biotechs burn through cash rapidly, optimizing operating cash flow can be essential to a company's financial health. Is cash being applied efficiently to maximize sales while minimizing the cost of R&D? Perhaps the most powerful way to maximize revenue potential and minimize cost is through label expansion.

    Companies with nascent revenue streams must appropriately limit costs while fostering newfound more »

  • Three Future Winners and One Major Loser in the HCV Wars

    By Leo Sun - July 18, 2013 | Tickers: ABBV, BMY, GILD, IDIX

    The biotech industry is a cutthroat one, with companies constantly racing to get new treatments approved by the FDA ahead of their rivals. In my previous articles, I discussed treatments for cancer and diabetes, and how competition between major biotechs created increasingly innovative and effective treatments.

    Today I’d like to discuss another major disease - hepatitis C. The hepatitis C virus (HCV) affects an estimated 130-200 million people worldwide, and more »

  • A Fundamentally Strong Biotech Stock

    By Kanak Kanti - July 17, 2013 | Tickers: ABBV, BMY, CELG, ONXX

    Celgene (NASDAQ: CELG) surged 7% on Thursday, July 11, 2013 on news that the Phase III trials of Revlimid /dexamethasone combination showed that it could be an initial treatment for newly diagnosed multiple myeloma patients. This is indeed good news for the company after reports that Britain’s National Institute for Health and Care Excellence (NICE) may not recommend it for myelodysplastic syndromes in the U.K.

    Revlimid, Celegene’s more »

  • Huge Potential For First Line Therapy For Frozen Shoulder

    By Kanak Kanti - July 17, 2013 | Tickers: ABBV, AUXL, HALO

    Editor's Note: This article has been amended to better describe Auxilium's drugs and pipeline prospects. Motley Fool apologizes for the inaccuracies.

    Xiaflex from Auxilium Pharmaceuticals (NASDAQ: AUXL) is used to treat Dupuytren’s contracture. The drug recently increased its revenue potential after announcing a positive outcome for the treatment of Frozen Shoulder Syndrome (FSS), a related disease that affects one in 20 adults worldwide. If approved, Xiaflex will more »

  • Why One of My Favorite Healthcare Companies Is Too Expensive

    By Matthew Frankel - July 15, 2013 | Tickers: ABT, ABBV, HOLX

    Abbott Labs (NYSE: ABT) has been one of the biggest players in the healthcare sector for many years, but a lot of changes have been taking place within the company. Most significantly, Abbott spun off its research-based pharmaceuticals business on the first of the year, creating the new entity AbbVie (NYSE: ABBV). In its current form, Abbott produces nutritionals, diagnostic products, generic medications, and medical devices. With a great balance more »

  • How Valuable Is a Cheaper Treatment for Arthritis?

    By Kanak Kanti - July 15, 2013 | Tickers: ABBV, AMGN, HSP, JNJ

    Arthritis biologics like Remicade, Enbrel, and Humira are pricy drugs that many of the 50 million American arthritis patients – and hundreds of millions of patients worldwide – might not be able to afford. On the other hand, cheaper generic drugs are not as effective. Now, Hospira (NYSE: HSP) is developing Inflectra, a biosimilar for Remicade, that will be safer and more effective than generic options, but at a fraction of the more »

  • A Developing "Breakthrough" In Biotechnology that You Should Monitor

    By Sherrie Stone - July 12, 2013 | Tickers: ABBV, JNJ, PCYC

    For many years, biopharmaceutical companies, physicians, patients, and investors alike, have been seeking a quicker regulatory path for drugs that demonstrate superior clinical evidence and treat life-threatening diseases. In 2012, the FDA showed signs of progress, with the creation of the “Breakthrough Therapy” designation. Now, it’s crunch time, as the FDA must prove that this designation actually means something to patients, physicians, companies, and Wall Street.

    A “Breakthrough” Submission more »

  • Which Company Needs a HCV Win?

    By Brandy Betz - July 11, 2013 | Tickers: ABBV, GILD, MRK | Editor's Choice

    The upcoming all-oral hepatitis C treatments earned well-deserved attention for some staggering cure rates, particularly in patient groups who haven’t responded well to the current drugs.

    Merck (NYSE: MRK) was one of the big HCV players -- but that’s about to change with Gilead (NASDAQ: GILD) and AbbVie (NYSE: ABBV) leading the new guard. How much does an HCV foothold mean to the overall health of these companies?

    Defending more »

  • Why Investors Should Care About Hepatitis C

    By Nick Chiu - July 9, 2013 | Tickers: ABT, ABBV, ACHN, GILD

    Hepatitis C, caused by the hepatitis C virus (HCV), is an infectious disease affecting the liver. An estimated 130 million-200 million people worldwide are infected with hepatitis C, and more than 350,000 people die every year from hepatitis C-related liver diseases.


    HCV is the most common chronic blood-borne infection in the United States and the leading cause of liver transplants, according to the Centers for Disease Control and more »

  • Do Generic Drugs Drastically Alter Market Dynamics?

    By Kanak Kanti - July 9, 2013 | Tickers: ABBV, ACT, AMGN

    Pharma companies have been paying off generic drug makers so that cheap generic drugs do not enter the market. In a settlement case involving AbbVie (NYSE: ABBV), the U.S. Supreme Court dealt a blow to this practice, allowing the FTC to take action against these deals. The judgment is seen as a “significant victory for the consumers and free trade.” However, the market remains relatively unaffected.

    The case

    The more »

  • Is This Pharmaceutical Giant About To Lose Its Cornerstone Drug?

    By Ryan Guenette - July 1, 2013 | Tickers: ABBV, HSP, JNJ, PFE

    What’s the worst nightmare of all pharmaceutical companies? Generics. They might as well be the grim reaper in the eyes of the brand-name pharmaceuticals. Generics completely destroy the pricing power and monopoly one company possesses on a particular drug, costing that particular company billions in lost revenue. Just one example of the devastating effects generics have on the original patent holding company is displayed in the case of Lipitor more »

  • 5 Spun-off Dividend Stocks for Strong Returns

    By Meena Krishnamsetty - June 30, 2013 | Tickers: ABBV, NCT, PFE, SAI, SI

    Spin-offs, or parent companies which themselves spin off business units, have historically outperformed the market following the event as management is better able to focus on its core business. As a result, some hedge funds like to identify spin-off opportunities as sources of potential strong returns (learn more about investing in spinoffs) and we think that investors who have a holding period of a few months to a few years more »

  • This Biotech Leader Is Poised to Outperform

    By Andrés Cardenal - June 26, 2013 | Tickers: ABBV, GILD, JNJ, MRK | Editor's Choice

    Investing in biotech companies can be risky; developing new drugs is a long, expensive, and uncertain process, and there is always considerable regulatory risk in the industry. When it comes to Gilead (NASDAQ: GILD), however, its dominant position in HIV treatment and the company’s growth prospects make it look like a long term winner.


    Gilead is the undisputed leader in HIV treatments; the company makes more than 75 more »

  • AbbVie Has Much More Upside Reward Than Downside Risk

    By Nick Chiu - June 25, 2013 | Tickers: ABBV, GILD, PFE

    For investors viewing AbbVie (NYSE: ABBV) as a value play since its spin-off from Abbott, it is time to think again. The management has always viewed AbbVie as a long-term growth play that still has strong potential from Humira and AbbVie’s pipeline.

    Since its separation from Abbott on Jan. 2, AbbVie has been operating smoothly with a simple business model and dedicated priorities. The company is focused on Humira more »

  • This Healthcare Giant is Definitely a Great Buy Now

    By Anh HOANG - June 25, 2013 | Tickers: ABT, ABBV, JNJ

    I am always excited when a company plans to return more cash to its shareholders in both dividends and share buybacks. Recently, Abbott Laboratories (NYSE: ABT) declared a quarterly dividend of 14 cents per share. Moreover, the company’s board has also authorized a $3 billion share buyback program to replace a $5 billion buyback program that was recently completed. Is Abbott a buy after a recent announcement of both more »

  • "Pay-For Delay" Was Fun While It Lasted

    By Sherrie Stone - June 18, 2013 | Tickers: ABBV, ACT, PFE

    When the FTC and the U.S. Supreme Court start breathing down your neck it’s not a pleasant thing, and could become very expensive for certain companies. Yet, not many people are talking about the trouble that generic and brand-name drug makers are finding themselves in.

    Uncovering a costly practice

    Last year, the FTC uncovered a number of agreements between large pharma and generic drug companies, which it called more »

  • Page 1 of 3